TY - JOUR
T1 - The next “sweet” spot for pancreatic ductal adenocarcinoma
T2 - Glycoprotein for early detection
AU - Xu, Yuanwei
AU - Wang, Yuefan
AU - Höti, Naseruddin
AU - Clark, David J.
AU - Chen, Shao Yung
AU - Zhang, Hui
N1 - Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Pancreatic ductal adenocarcinoma (PDAC) is the most common neoplastic disease of the pancreas, accounting for more than 90% of all pancreatic malignancies. As a highly lethal malignancy, PDAC is the fourth leading cause of cancer-related deaths worldwide with a 5-year overall survival of less than 8%. The efficacy and outcome of PDAC treatment largely depend on the stage of disease at the time of diagnosis. Surgical resection followed by adjuvant chemotherapy remains the only possibly curative therapy, yet 80%–90% of PDAC patients present with nonresectable PDAC stages at the time of clinical presentation. Despite our advancing knowledge of PDAC, the prognosis remains strikingly poor, which is primarily due to the difficulty of diagnosing PDAC at the early stages. Recent advances in glycoproteomics and glycomics based on mass spectrometry have shown that aberrations in protein glycosylation plays a critical role in carcinogenesis, tumor progression, metastasis, chemoresistance, and immuno-response of PDAC and other types of cancers. A growing interest has thus been placed upon protein glycosylation as a potential early detection biomarker for PDAC. We herein take stock of the advancements in the early detection of PDAC that were carried out with mass spectrometry, with special focus on protein glycosylation.
AB - Pancreatic ductal adenocarcinoma (PDAC) is the most common neoplastic disease of the pancreas, accounting for more than 90% of all pancreatic malignancies. As a highly lethal malignancy, PDAC is the fourth leading cause of cancer-related deaths worldwide with a 5-year overall survival of less than 8%. The efficacy and outcome of PDAC treatment largely depend on the stage of disease at the time of diagnosis. Surgical resection followed by adjuvant chemotherapy remains the only possibly curative therapy, yet 80%–90% of PDAC patients present with nonresectable PDAC stages at the time of clinical presentation. Despite our advancing knowledge of PDAC, the prognosis remains strikingly poor, which is primarily due to the difficulty of diagnosing PDAC at the early stages. Recent advances in glycoproteomics and glycomics based on mass spectrometry have shown that aberrations in protein glycosylation plays a critical role in carcinogenesis, tumor progression, metastasis, chemoresistance, and immuno-response of PDAC and other types of cancers. A growing interest has thus been placed upon protein glycosylation as a potential early detection biomarker for PDAC. We herein take stock of the advancements in the early detection of PDAC that were carried out with mass spectrometry, with special focus on protein glycosylation.
UR - http://www.scopus.com/inward/record.url?scp=85118881096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118881096&partnerID=8YFLogxK
U2 - 10.1002/mas.21748
DO - 10.1002/mas.21748
M3 - Review article
C2 - 34766650
AN - SCOPUS:85118881096
SN - 0277-7037
VL - 42
SP - 822
EP - 843
JO - Mass Spectrometry Reviews
JF - Mass Spectrometry Reviews
IS - 2
ER -